Nirsevimab at 44.7% coverage averted 204,306 RSV medically attended lower respiratory tract diseases, including a 42% reduction in hospitalizations, projecting up to 86% reduction with universal coverage in US infants.
Does nirsevimab reduce RSV-related medically attended lower respiratory tract disease in US infants compared to the pre-2023 standard of practice?
Nirsevimab prophylaxis at observed and expanded coverage levels substantially reduces the public health burden of infant RSV, supporting efforts toward universal immunization.
Effect estimate: 42% reduction in hospitalizations, 39% reduction in ER and primary care visits at 44.7% coverage; up to 86% reduction in MA-LRTDs at 100% coverage
Absolute Event Rate: 319289% vs 523594%
Nirsevimab has already achieved substantial reductions in RSV-associated clinical burden at current national coverage levels. Modeled increases in coverage demonstrate large, incremental public health gains with complete universal immunization yielding up to an 86% reduction in RSV MA-LRTDs. These findings highlight the importance of implementing strategies that enhance access, reduce inequities, and support higher, sustained coverage to maximize population-level benefits of RSV prophylaxis.
Yarnoff et al. (Thu,) conducted a other in Infants in the United States at risk of RSV medically attended lower respiratory tract disease during the 2024–2025 RSV season. Nirsevimab vs. Pre-2023 Standard of Practice with palivizumab only for high-risk infants (82% coverage) was evaluated on Medically attended RSV lower respiratory tract disease (MA-LRTD), including hospitalizations, emergency room visits, primary care visits, and RSV-related deaths (42% reduction in hospitalizations, 39% reduction in ER and primary care visits at 44.7% coverage; up to 86% reduction in MA-LRTDs at 100% coverage). Nirsevimab at 44.7% coverage averted 204,306 RSV medically attended lower respiratory tract diseases, including a 42% reduction in hospitalizations, projecting up to 86% reduction with universal coverage in US infants.